Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous ligand's action.
Direct-Acting Cholinergic Agonists: Therapeutic Uses01:11

Direct-Acting Cholinergic Agonists: Therapeutic Uses

Direct-acting cholinergic agonists have many therapeutic uses in various medical fields. Choline esters, including acetylcholine, have limited clinical utility due to their non-selectivity and short duration of action. Still, acetylcholine and carbachol are applied topically during ophthalmologic surgery to induce miosis. Pilocarpine, a muscarinic and ganglionic stimulator, effectively treats open-angle glaucoma and alleviates xerostomia and dry mouth caused by radiotherapy or Sjögren syndrome.
Cholinergic Antagonists: Therapeutic Uses01:26

Cholinergic Antagonists: Therapeutic Uses

Antimuscarinic drugs have various therapeutic applications by inhibiting parasympathetic stimulation in different systems. Here are the key therapeutic uses of antimuscarinics:    
Respiratory Tract: Ipratropium, aclidinium, and tiotropium treat asthma, chronic bronchitis, and chronic obstructive pulmonary disease (COPD). They protect against bronchoconstriction caused by irritants like cigarette smoke, sulfur dioxide, and ozone. They also help reduce nasopharyngeal secretions in common...
Adrenergic Agonists: Therapeutic Classification01:18

Adrenergic Agonists: Therapeutic Classification

Adrenergic agonists can be classified based on their therapeutic uses and mechanisms of action. They serve various purposes in clinical applications.
Vasopressor or pressor agents: They increase blood pressure and function as cardiac stimulants. Examples include endogenous catecholamines (norepinephrine and dopamine) and synthetic agents (phenylephrine).
Bronchodilators: β2-agonists can relax bronchial muscles and widen airways. They are commonly used for treating obstructive pulmonary...
Adrenergic Agonists: Therapeutic Uses01:30

Adrenergic Agonists: Therapeutic Uses

Adrenergic agonists have diverse therapeutic uses across various medical conditions and emergencies.
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and anaphylaxis:...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

"Universal Warming" protocol for vitrified oocytes to streamline cell exchange for transnational donation programs: a multi-center study.

Journal of assisted reproduction and genetics·2020
Same author

Testing the efficacy and efficiency of a single "universal warming protocol" for vitrified human embryos: prospective randomized controlled trial and retrospective longitudinal cohort study.

Journal of assisted reproduction and genetics·2018
Same author

A prospective, randomised, investigator-blind, controlled, clinical study on the clinical efficacy and tolerability of two highly purified hMG preparations administered subcutaneously in women undergoing IVF.

Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology·2013
Same author

A plea for a more physiological ICSI.

Andrologia·2012
Same author

Efficiency of aseptic open vitrification and hermetical cryostorage of human oocytes.

Reproductive biomedicine online·2011
Same author

Long-term cryostorage does not adversely affect the outcome of oocyte thawing cycles.

Reproductive biomedicine online·2009

Related Experiment Video

Updated: Jul 26, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

GnRH agonists and antagonists. Current clinical status.

M Filicori1, C Flamigni

  • 1Department of Obstetrics and Gynecology, University of Bologna.

Drugs
|January 1, 1988
PubMed
Summary

Gonadotrophin-releasing hormone (GnRH) analogues provide non-steroidal control of reproductive hormones. While effective for various conditions, their contraceptive use is limited, but new formulations and GnRH antagonists show promise for expanded clinical applications.

More Related Videos

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
09:28

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Related Experiment Videos

Last Updated: Jul 26, 2026

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice
07:09

The Sciatic Nerve Cuffing Model of Neuropathic Pain in Mice

Published on: July 16, 2014

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat
09:28

A Method of Nodose Ganglia Injection in Sprague-Dawley Rat

Published on: November 25, 2014

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
10:36

In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues

Published on: March 21, 2017

Area of Science:

  • Reproductive Endocrinology
  • Pharmacology

Background:

  • Gonadotrophin-releasing hormone (GnRH) analogues represent a significant advancement in non-steroidal reproductive endocrine axis manipulation.
  • GnRH agonists are established treatments for conditions including precocious puberty, various cancers, endometriosis, uterine fibroids, and polycystic ovarian disease.

Purpose of the Study:

  • To review the current applications of GnRH analogues in managing reproductive endocrine disorders.
  • To discuss the limitations of GnRH agonists, particularly in contraception.
  • To explore the potential of novel formulations and GnRH antagonists for optimizing clinical use.

Main Methods:

  • Literature review of GnRH analogue applications.
  • Analysis of clinical efficacy and limitations.
  • Discussion of emerging GnRH agonist formulations and GnRH antagonists.

Main Results:

  • GnRH agonists demonstrate broad efficacy in treating numerous hormone-dependent conditions.
  • Contraceptive applications of current GnRH agonists have yielded disappointing results.
  • Slow-release depot formulations and GnRH antagonists offer potential improvements.

Conclusions:

  • GnRH analogues are versatile tools in reproductive endocrinology.
  • Further development in formulation and antagonist design is crucial for expanding therapeutic roles, especially in contraception.